Moderate Valve Oversizing During TAVR Boosts Survival—Too Much May Be Less Beneficial

Why It Matters

Moderate oversizing offers a clear survival advantage, guiding clinicians toward evidence‑based sizing that balances safety and efficacy in TAVR procedures.

Key Takeaways

• Moderate oversizing (10‑20%) cuts all‑cause mortality.
• Minimal and severe oversizing show no survival advantage.
• Paravalvular leak rates unchanged across sizing groups.
• Balloon‑expandable valves clustered in minimal‑oversizing cohort.
• Individualized sizing essential per valve type and anatomy.

Pulse Analysis

Transcatheter aortic valve replacement (TAVR) has become the preferred therapy for most patients with severe aortic stenosis, yet the technical nuances of valve deployment remain a focal point for interventional cardiologists. One of the most contentious variables is the degree of annular oversizing, which balances secure anchoring against the risk of complications such as annular rupture, conduction disturbances, or paravalvular leak. Early generations of balloon‑expandable and self‑expanding devices often prompted operators to adopt either aggressive or conservative sizing strategies, creating a split in clinical practice that persisted despite evolving device profiles.

The recent analysis by Ogami et al., encompassing more than 1,800 patients treated at a high‑volume U.S. center between 2020 and 2025, provides robust evidence that a moderate oversizing window of 10 % to 20 % delivers the most favorable survival signal. Patients in this cohort experienced a statistically significant reduction in all‑cause mortality, while procedural metrics—including stroke, vascular complications, and need for pacemaker implantation—remained comparable to those with minimal or severe oversizing. Notably, the incidence of paravalvular leak was low and uniform across all groups, suggesting that modest oversizing does not compromise sealing performance.

These findings reinforce the American College of Cardiology’s recommendation for a ‘small degree of oversizing’ and suggest that excessive enlargement, particularly with balloon‑expandable platforms, may offer diminishing returns or heightened risk. Clinicians should therefore integrate precise annular imaging, valve‑specific radial force characteristics, and patient‑specific risk scores when selecting the optimal oversizing percentage. As next‑generation transcatheter heart valves incorporate adaptive sealing skirts and lower profile delivery systems, the margin for error narrows, making individualized sizing strategies even more critical for long‑term outcomes and cost‑effectiveness.